ASCO 2012 Live Blog -- Monday

CHICAGO ( TheStreet) --Welcome to TheStreet's live-blog coverage of the American Society of Clinical Oncology (ASCO) annual meeting. It's Monday, the third full day of data presentations at the largest annual gathering of cancer drug researchers in the world. More importantly, investors get the first chance to trade cancer drug stocks today following a weekend of data presentations.

On the schedule for today: An important update from Ariad Pharmaceuticals ( ARIA) and the pivotal study of ponatinib in chronic myeloid leukemia. Also, presentation from Onyx Pharmaceuticals ( ONXX) and Bayer of phase III data from a study of regorafenib in gastrointestinal stromal tumors (GIST).

Also watch for data presentations from Array Biopharma ( ARRY), Seattle Genetics ( SGEN) Amgen ( AMGN), Roche ( RHHBY), Pharmacyclics ( PCYC).

Follow this live blog throughout the day for continuous updates and reports from the ASCO meeting. I'll be reporting on clinical data presentations as I see and hear them, and I'll be blogging from the hallways, exhibition hall and meeting rooms, giving you a real-time perspective on the investor-worthy buzz.

The blog will also capture tweets from a select and experienced group of analysts, doctors and journalists -- all of whom will add their perspective and insight into the ASCO meeting.

I welcome your comments and questions on this live blog, too, which I'll do my best to answer and publish as time permits.

--Written by Adam Feuerstein in Chicago.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.

Follow TheStreet on Twitter and become a fan on Facebook.
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

If you liked this article you might like

After Soaring to $150, Can Incyte Stir Up More Upside?

Biotech Buoyed by Deal Talk

The Next Target in Biotech Land

The Next Target in Biotech Land

Earnings Key to Next Week's Winners: Cramer's 'Mad Money' Recap (Friday 1/13/17)